260 related articles for article (PubMed ID: 35190936)
41. Assessment of humoral and cellular immune responses to SARS CoV-2 vaccination (BNT162b2) in immunocompromised renal allograft recipients.
Zhang R; Shin BH; Gadsden TM; Petrosyan A; Vo A; Ammerman N; Sethi S; Huang E; Peng A; Najjar R; Atienza J; Kim I; Jordan SC
Transpl Infect Dis; 2022 Apr; 24(2):e13813. PubMed ID: 35202497
[TBL] [Abstract][Full Text] [Related]
42. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.
Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M
PLoS One; 2022; 17(6):e0269917. PubMed ID: 35687563
[TBL] [Abstract][Full Text] [Related]
43. Long-lasting T-cell response to SARS-CoV-2 antigens after vaccination-a prospective cohort study of HCWs working with COVID-19 patients.
Krifors A; Freyhult E; Rashid Teljebäck M; Wallin RPA; Winqvist O; Månsson E
Infect Dis (Lond); 2023 Feb; 55(2):142-148. PubMed ID: 36369711
[TBL] [Abstract][Full Text] [Related]
44. Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine.
Ciabattini A; Pastore G; Lucchesi S; Montesi G; Costagli S; Polvere J; Fiorino F; Pettini E; Lippi A; Ancillotti L; Tumbarello M; Fabbiani M; Montagnani F; Medaglini D
Cells; 2023 Jun; 12(13):. PubMed ID: 37443740
[TBL] [Abstract][Full Text] [Related]
45. SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals.
Ruggiero A; Piubelli C; Calciano L; Accordini S; Valenti MT; Carbonare LD; Siracusano G; Temperton N; Tiberti N; Longoni SS; Pizzato M; Accordini S; ; Fantoni T; Lopalco L; Beretta A; Bisoffi Z; Zipeto D
EBioMedicine; 2022 Mar; 77():103888. PubMed ID: 35196644
[TBL] [Abstract][Full Text] [Related]
46. T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents.
Schiavoni I; Palmieri A; Olivetta E; Leone P; Di Lonardo A; Mazzoli A; Cafariello C; Malara A; Palamara AT; Incalzi RA; Onder G; Stefanelli P; Fedele G;
J Am Med Dir Assoc; 2023 Feb; 24(2):140-147.e2. PubMed ID: 36587928
[TBL] [Abstract][Full Text] [Related]
47. T-Cell Defects Associated to Lack of Spike-Specific Antibodies after BNT162b2 Full Immunization Followed by a Booster Dose in Patients with Common Variable Immune Deficiencies.
Pulvirenti F; Di Cecca S; Sinibaldi M; Piano Mortari E; Terreri S; Albano C; Guercio M; Sculco E; Milito C; Ferrari S; Locatelli F; Quintarelli C; Carsetti R; Quinti I
Cells; 2022 Jun; 11(12):. PubMed ID: 35741048
[TBL] [Abstract][Full Text] [Related]
48. COVID-19 Severity, Cardiological Outcome, and Immunogenicity of mRNA Vaccine on Adult Patients With 22q11.2 DS.
Pulvirenti F; Mortari EP; Putotto C; Terreri S; Fernandez Salinas A; Cinicola BL; Cimini E; Di Napoli G; Sculco E; Milito C; Versacci P; Agrati C; Marino B; Carsetti R; Quinti I
J Allergy Clin Immunol Pract; 2023 Jan; 11(1):292-305.e2. PubMed ID: 36280136
[TBL] [Abstract][Full Text] [Related]
49. Dynamics of SARS-CoV-2 Spike-IgG throughout Three COVID-19 Vaccination Regimens: A 21-Month Longitudinal Study of 82 Norwegian Healthcare Workers.
Augustinussen MH; Tylden GD; Rinaldo CH
Viruses; 2023 Feb; 15(3):. PubMed ID: 36992328
[TBL] [Abstract][Full Text] [Related]
50. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
51. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
[TBL] [Abstract][Full Text] [Related]
52. 6 month serologic response to the Pfizer-BioNTech COVID-19 vaccine among healthcare workers.
Cham J; Pandey AC; New J; Huynh T; Hong L; Orendain N; Topol EJ; Nicholson LJ
PLoS One; 2022; 17(4):e0266781. PubMed ID: 35436296
[TBL] [Abstract][Full Text] [Related]
53. SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best.
Salinas AF; Mortari EP; Terreri S; Quintarelli C; Pulvirenti F; Di Cecca S; Guercio M; Milito C; Bonanni L; Auria S; Romaggioli L; Cusano G; Albano C; Zaffina S; Perno CF; Spadaro G; Locatelli F; Carsetti R; Quinti I
J Clin Immunol; 2021 Nov; 41(8):1709-1722. PubMed ID: 34669144
[TBL] [Abstract][Full Text] [Related]
54. Comparison of Maternal and Neonatal Antibody Levels After COVID-19 Vaccination vs SARS-CoV-2 Infection.
Flannery DD; Gouma S; Dhudasia MB; Mukhopadhyay S; Pfeifer MR; Woodford EC; Briker SM; Triebwasser JE; Gerber JS; Morris JS; Weirick ME; McAllister CM; Hensley SE; Puopolo KM
JAMA Netw Open; 2022 Nov; 5(11):e2240993. PubMed ID: 36350652
[TBL] [Abstract][Full Text] [Related]
55. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
56. Prior SARS-CoV-2 Infection Enhances Initial mRNA Vaccine Response with a Lower Impact on Long-Term Immunity.
Silva-Moraes V; Souquette A; Sautto GA; Paciello I; Antonelli G; Andreano E; Rappuoli R; Teixeira-Carvalho A; Ross TM
Immunohorizons; 2023 Oct; 7(10):635-651. PubMed ID: 37819998
[TBL] [Abstract][Full Text] [Related]
57. [Comparative Analyses of IgA Antibody Response of Non-COVID-19 Infected People Over 60 Years Old Following CoronaVac and Pfizer-BioNTech COVID-19 Vaccination].
Yürüker Ö; Yetkin O; Güvenir M
Mikrobiyol Bul; 2023 Apr; 57(2):330-333. PubMed ID: 37067217
[TBL] [Abstract][Full Text] [Related]
58. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
Casas Fischer R
Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
[TBL] [Abstract][Full Text] [Related]
59. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
Epsi NJ; Richard SA; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Fries AC; Maves RC; Colombo RE; Larson DT; Smith A; Chi SW; Maldonado CJ; Ewers EC; Jones MU; Berjohn CM; Libraty DH; Edwards MS; English C; Rozman JS; Mody RM; Colombo CJ; Samuels EC; Nwachukwu P; Tso MS; Scher AI; Byrne C; Rusiecki J; Simons MP; Tribble D; Broder CC; Agan BK; Burgess TH; Laing ED; Pollett SD;
Clin Infect Dis; 2023 Feb; 76(3):e439-e449. PubMed ID: 35608504
[TBL] [Abstract][Full Text] [Related]
60. Characterizing Longitudinal Antibody Responses in Recovered Individuals Following COVID-19 Infection and Single-Dose Vaccination: A Prospective Cohort Study.
Olmstead AD; Nikiforuk AM; Schwartz S; Márquez AC; Valadbeigy T; Flores E; Saran M; Goldfarb DM; Hayden A; Masud S; Russell SL; Prystajecky N; Jassem AN; Morshed M; Sekirov I
Viruses; 2022 Oct; 14(11):. PubMed ID: 36366515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
